Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
AN2 Therapeutics, Inc. | Chief Strategy Officer | Common Stock | 31.9K | $610K | $19.11 | Mar 15, 2024 | Direct |
AN2 Therapeutics, Inc. | Chief Strategy Officer | Stock Option (right to buy) | 60K | Mar 15, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ANTX | AN2 Therapeutics, Inc. | Mar 15, 2024 | 1 | $0 | 4/A | Mar 29, 2024 | Chief Strategy Officer |
ANTX | AN2 Therapeutics, Inc. | Mar 15, 2024 | 2 | $0 | 4 | Mar 18, 2024 | Chief Strategy Officer |
ANTX | AN2 Therapeutics, Inc. | Jan 9, 2024 | 5 | -$115K | 4 | Jan 11, 2024 | Chief Strategy Officer |
ANTX | AN2 Therapeutics, Inc. | Jan 2, 2024 | 3 | -$50.9K | 4 | Jan 4, 2024 | Chief Strategy Officer |
ANTX | AN2 Therapeutics, Inc. | Feb 15, 2023 | 1 | $0 | 4 | Feb 17, 2023 | Chief Strategy Officer |
ANTX | AN2 Therapeutics, Inc. | May 12, 2022 | 1 | $0 | 4 | May 16, 2022 | Chief Strategy Officer |
ANTX | AN2 Therapeutics, Inc. | Mar 24, 2022 | 0 | $0 | 3 | Mar 24, 2022 | Chief Strategy Officer |